Brown Advisory
SWTX

Brown Advisory’s SpringWorks Therapeutics SWTX Stock Holding History

Brown Advisory’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,902
Closed -$366K – 1241
2021
Q4 		$366K Buy
+5,902
New +$391K ﹤0.01% 975

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Brown Advisory's SWTX Position: Q1 2022 in Review

Brown Advisory sold out of SpringWorks Therapeutics (SWTX) in Q1 2022, closing a stake of 5,902 shares — an estimated $366K sold.

Brown Advisory first reported a position in SWTX in Q4 2021 and held it in 1 quarter. The position peaked at $366K in Q4 2021. 137 funds tracked by Wall St. Rank hold SWTX as of Q1 2022.

  • Brown Advisory reported no remaining SpringWorks Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Brown Advisory sold 5,902 SpringWorks Therapeutics shares in Q1 2022, an estimated $366K.
  • Brown Advisory first reported a position in SpringWorks Therapeutics in Q4 2021 and held it in 1 quarter.
  • Brown Advisory's SpringWorks Therapeutics position peaked at $366K in Q4 2021.
  • 137 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2022.

Based on Brown Advisory's 13F filing for Q1 2022, filed 9 May 2022.